Bangavax 100% effective against 11 variants
Published: 11:14 AM, 18 October 2021 Updated: 05:06 PM, 18 October 2021
The ongoing pre-clinical trials of home-grown Covid-19 shot Bangavax showed that it is cent percent effective against 11 variants of the coronavirus, Globe Biotech Limited claimed.
According to the local pharmaceutical company, the trial of the Bangavax vaccine on animals (monkeys) will end on Thursday.
Globe Biotech senior manager (quality and regulatory operations) Dr Mohammad Mohiuddin confirmed the information to media on Monday.
The trials on monkeys started on August 1 and will end on Thursday, he said adding that the detailed report on the trial is likely to be handed over to the Bangladesh Medical Research Council (BMRC) next week.
"We've got a very good response… as their vaccine helps develop antibody among the inoculated monkeys to fight out 11 coronavirus forms, including the Delta variant," he said.
Dr Mohiuddin said the vaccinated monkeys responded well as the shots were found safe for them.
They also did a 'virus challenge study' with analysing sequence of the mutants and matched it with their vaccine and found the antidote very effective against them, according to him.
Globe Biotech administered Bangavax to the monkeys that helped develop effective antibody among them. Later, all the 11 variants were pushed in to the animals to see whether they caught the viral disease.
"Alhamdulillah [the Almighty be praised], no monkey is down with the virus, meaning that the antibody helps neutralise the pathogen in a few days," Dr Mohiuddin added.
Earlier in October last year, Globe announced that its mRNA vaccine showed promise in trials on mice. Based on the successful trials, it approached the BMRC for ethical clearance before human trials.